Patient acceptability of CITOBOT for cervical cancer screening: A mixed-method study
PLOS One · 2025
DOI: 10.1371/journal.pone.0325805 ↗Kurz gefasst
Mixed-Methods-Studie in der Zeitschrift PLOS One, 2025. Verfasst von Marcela Arrivillaga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Epidemiology, Pontificia Universidad Javeriana Cali, Cali, Colombia. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Early Detection of Cancer, Patient Acceptance of Health Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technology and Innovation, Pontificia Universidad Javeriana.
Abstract (Originalsprache)
This study assessed the acceptability of CITOBOT, a device for early cervical cancer screening in a real-world pilot setting as part of a translational research project aimed at designing and clinically validating a portable, cost-effective device supported by artificial intelligence. The authors adopted the Theoretical Framework of Acceptability for its utility in evaluating patient acceptability within complex interventions’ development, piloting, and feasibility phases. We employed a mixed-method study, with 20 consecutive participants recruited from a specialized cancer healthcare center in Cali, Colombia. Data collection included a sociodemographic, gynecological-obstetric, behavioral survey, a validated patient acceptability scale, alongside open-ended interview questions. No adverse effects were reported seven days post-testing. The findings were promising, with all participants expressing high overall acceptability. Retrospective acceptability, focusing on the evaluation after device pilot testing, revealed that participants felt comfortable with the device, found it coherent with the purpose of early cervical cancer detection, and did not perceive the test as an additional burden compared to conventional cytology screening. Regarding prospective acceptability, which assesses anticipated acceptability before full implementation, three results stand out: i) All participants stated that they would intend to attend their health service if called for testing with CITOBOT; ii) they perceived opportunity costs, such as timely delivery of results, expedited diagnosis and treatment, and improved accessibility for women with limited resources or geographical barriers to healthcare access; and iii) participants viewed CITOBOT as highly effective in preventing cervical cancer deaths, indicating a strong belief in its potential to impact public health outcomes positively. Addressing concerns related to discomfort, inconvenience, and timely delivery of results, CITOBOT shows promise in enhancing cervical cancer screening participation and adherence, especially among underserved populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Public Health and Epidemiology, Pontificia Universidad Javeriana Cali, Cali, Colombia.
- Department of Maternal and Child Health, Pontificia Universidad Javeriana Cali, Cali, Colombia.
- Red de Salud Ladera ESE, Alcaldía de Cali, Cali, Colombia.
- Department of Electronics and Computer Sciences. Pontificia Universidad Javeriana Cali, Cali, Colombia.
- Faculty of Health Sciences, Universidad Icesi & Centro de Investigaciones Clínicas Fundación Valle del Lili, Cali, Colombia.
ORCID-Profile: Marcela Arrivillaga, Juan Pablo García-Cifuentes, Paula C Bermúdez
Förderung
- Ministry of Science, Technology and Innovation
- Pontificia Universidad Javeriana
Zitieren
APA
Arrivillaga, M., Torres, M. D. M., Neira, D., García-Cifuentes, J. P., Vargas-Cardona, H. D., Rodríguez-López, M., & Bermúdez, P. C. (2025). Patient acceptability of CITOBOT for cervical cancer screening: A mixed-method study. PLOS One. https://doi.org/10.1371/journal.pone.0325805
Vancouver
Arrivillaga M, Torres MDM, Neira D, García-Cifuentes JP, Vargas-Cardona HD, Rodríguez-López M, et al. Patient acceptability of CITOBOT for cervical cancer screening: A mixed-method study. PLOS One. 2025. doi:10.1371/journal.pone.0325805
BibTeX
@article{Arrivillaga2025,
author = {Arrivillaga, Marcela and Torres, Maria Del Mar and Neira, Daniela and García-Cifuentes, Juan Pablo and Vargas-Cardona, Hernán Dario and Rodríguez-López, Mérida and Bermúdez, Paula C},
title = {Patient acceptability of CITOBOT for cervical cancer screening: A mixed-method study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0325805}
}
EUVIMED